Feasibility of Endoscopic Pylorotomy in the Treatment of Refractory Gastroparesis, Pilot Study. (GASTROPOP)
Primary Purpose
Gastroparesis
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
per oral pylorotomy
Sponsored by
About this trial
This is an interventional treatment trial for Gastroparesis focused on measuring refractory gastroparesis, per oral pyloromyotomy
Eligibility Criteria
Inclusion Criteria:
- Patient with refractory gastroparesis to drug treatment (post-diabetic, post-Sjogren, postsurgical or idiopathic)
- Signed Consent
- Affiliate or beneficiary of a French social security scheme
Exclusion Criteria:
- Contraindications to gastroesophageal gastroduodenal endoscopy,
- Early Unable to follow protocol,
- Contraindications to general anesthesia,
- Can not Stop anticoagulants for the gesture,
- Can not stop antiplatelet agents for the gesture,
- Pregnant or lactating women,
- Gastric resection surgery History of pyloric
- Patients under guardianship, curatorship or safeguard justice,
- Disorders of hemostasis against-indicating the endoscopic procedure.
Sites / Locations
- CHU de LIMOGES
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Per oral pylorotomy
Arm Description
Patients with gastroparesis (significant prolongation of gastric emptying) not improved prokinetic and antiemetic treatments undergoing per oral pylorotomy
Outcomes
Primary Outcome Measures
Number of technical success for endoscopic pylorotomy on the total number of gestures.
Technical feasibility will be the feasibility of endoscopic pylorotomy gesture by the technique of the tunnel.
Secondary Outcome Measures
Incidence of adverse events of pylorotomy
analysis of adverse events during the 3 months following the pylorotomy (including perforation per-gesture, bleeding post-gesture)
Ratio between the diameter of the pyloric canal and the pyloric pressure
Evaluation of the pyloric compliance by the Endolumenal Functional Lumen Imaging Probe (EndoFLIP) system before the procedure and at 3 months, depending on etiology.
Assessment of gastric emptying scintigraphy
Assessment of gastric emptying scintigraphy before the procedure and at 3 months by measuring the half gastric emptying time and percentage retention to 4 hours
Assessment of gastroparesis severity symptom using the Gastroparesis Cardinal Symptom Index (GCSI)
Evaluation of the severity of gastroparesis symptom using the GCSI questionnaire
Assessment of Quality of Life in Upper Gastrointestinal Disorders (PAGI-QOL)
Evaluation of the quality of life of patient with Upper Gastrointestinal Disorders using PAGI-QOL questionnaire
Assessment of Quality of Life in Gastrointestinal disease (GIQLI)
Evaluation of quality of life of patients with gastrointestinal Disease using GIQLI questionnaire
Assessment of functional health and well-being from the patient's point of view (SF-36)
Evaluation of of functional health and well-being from the patient's point of view using SF-36 questionnaire
Consumption of gastric prokinetic drugs
Data collecting about domperidone, metoclopramide and erythromycin consumption.
Full Information
NCT ID
NCT02779920
First Posted
February 23, 2016
Last Updated
March 16, 2020
Sponsor
University Hospital, Limoges
1. Study Identification
Unique Protocol Identification Number
NCT02779920
Brief Title
Feasibility of Endoscopic Pylorotomy in the Treatment of Refractory Gastroparesis, Pilot Study.
Acronym
GASTROPOP
Official Title
Feasibility of Endoscopic Pylorotomy in the Treatment of Refractory Gastroparesis, Pilot Study.
Study Type
Interventional
2. Study Status
Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
April 2016 (Actual)
Primary Completion Date
June 2017 (Actual)
Study Completion Date
July 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Limoges
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Gastroparesis is a common chronic condition, disabling the limited therapeutic resources justifying the exploration of new therapeutic possibilities.
By analogy to the technique of Per Oral Endoscopic Myotomy (POEM), we believe that myotomy pyloric muscle (POP = Per Oral Pyloromyotomy) endoscopically could become a treatment of choice in the refractory gastroparesis with drug treatments by attacking the pyloric obstacle often spastic that counteracts an effective gastric emptying.
Detailed Description
Experimental study, prospective, single-center, POP feasibility pilot in the treatment of refractory gastroparesis.
Patients with gastroparesis (significant prolongation of gastric emptying) unimproved by prokinetic treatment and meet all the eligibility criteria will be included after a period of reflection of two weeks minimum.
20 patients will be prospectively included 10 patients with diabetic gastroparesis, 10 patients with non-diabetic gastroparesis (post-surgical, post-Sjogren, idiopathic).
POP will be performed under general anesthesia in intubated-ventilated patients using a carbon dioxide (CO2) inflator. The published standard technique and learned by our team on the pig model will be conducted: submucosal tunnel at the anterior surface of the gastric antrum starting 3-5 cm proximal to the pylorus front section to the fiber by fiber to the muscular pyloric, then closing the inlet tunnel by hemostatic clips.
An evaluation of symptoms by the Gastroparesis Cardinal Symptom Index (ISCC) of the quality of life of the patient Assessment of upper gastrointestinal disorders-Quality Of Life (PAGI-QoL), SF-36 and gastrointestinal Quality of Life Index (GIQLI ) and gastric emptying by a scintigraphic gastric emptying will be carried out at 3 months.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastroparesis
Keywords
refractory gastroparesis, per oral pyloromyotomy
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Per oral pylorotomy
Arm Type
Experimental
Arm Description
Patients with gastroparesis (significant prolongation of gastric emptying) not improved prokinetic and antiemetic treatments undergoing per oral pylorotomy
Intervention Type
Procedure
Intervention Name(s)
per oral pylorotomy
Intervention Description
The procedure is endoscopic pylorotomy. The standard procedure consists in the realization of a longitudinal incision of 2 cm at the anterior surface of the gastric antrum at 5 cm from the pylorus after a submucosal injection of a solution containing 85% saline 10% glycerol and 5% fructose. This longitudinal incision serve as an input for producing a submucosal tunnel dissected fibers gastric submucosa step. The internal circular of the pyloric muscle is then severed fiber after fiber over its entire length and its entire thickness. Once the pyloric section completed, the tunnel inlet will be closed by means of hemostatic clips.
Primary Outcome Measure Information:
Title
Number of technical success for endoscopic pylorotomy on the total number of gestures.
Description
Technical feasibility will be the feasibility of endoscopic pylorotomy gesture by the technique of the tunnel.
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Incidence of adverse events of pylorotomy
Description
analysis of adverse events during the 3 months following the pylorotomy (including perforation per-gesture, bleeding post-gesture)
Time Frame
3 months
Title
Ratio between the diameter of the pyloric canal and the pyloric pressure
Description
Evaluation of the pyloric compliance by the Endolumenal Functional Lumen Imaging Probe (EndoFLIP) system before the procedure and at 3 months, depending on etiology.
Time Frame
Baseline and 3 months
Title
Assessment of gastric emptying scintigraphy
Description
Assessment of gastric emptying scintigraphy before the procedure and at 3 months by measuring the half gastric emptying time and percentage retention to 4 hours
Time Frame
baseline and 3 months
Title
Assessment of gastroparesis severity symptom using the Gastroparesis Cardinal Symptom Index (GCSI)
Description
Evaluation of the severity of gastroparesis symptom using the GCSI questionnaire
Time Frame
Baseline, 1 month and 3 month
Title
Assessment of Quality of Life in Upper Gastrointestinal Disorders (PAGI-QOL)
Description
Evaluation of the quality of life of patient with Upper Gastrointestinal Disorders using PAGI-QOL questionnaire
Time Frame
Baseline, 1 month and 3 month
Title
Assessment of Quality of Life in Gastrointestinal disease (GIQLI)
Description
Evaluation of quality of life of patients with gastrointestinal Disease using GIQLI questionnaire
Time Frame
Baseline, 1 month and 3 month
Title
Assessment of functional health and well-being from the patient's point of view (SF-36)
Description
Evaluation of of functional health and well-being from the patient's point of view using SF-36 questionnaire
Time Frame
Baseline, 1 month and 3 month
Title
Consumption of gastric prokinetic drugs
Description
Data collecting about domperidone, metoclopramide and erythromycin consumption.
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient with refractory gastroparesis to drug treatment (post-diabetic, post-Sjogren, postsurgical or idiopathic)
Signed Consent
Affiliate or beneficiary of a French social security scheme
Exclusion Criteria:
Contraindications to gastroesophageal gastroduodenal endoscopy,
Early Unable to follow protocol,
Contraindications to general anesthesia,
Can not Stop anticoagulants for the gesture,
Can not stop antiplatelet agents for the gesture,
Pregnant or lactating women,
Gastric resection surgery History of pyloric
Patients under guardianship, curatorship or safeguard justice,
Disorders of hemostasis against-indicating the endoscopic procedure.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jérémie Jacques, MD
Organizational Affiliation
University Hospital, Limoges
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU de LIMOGES
City
Limoges
ZIP/Postal Code
87042
Country
France
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
29895073
Citation
Jacques J, Pagnon L, Hure F, Legros R, Crepin S, Fauchais AL, Palat S, Ducrotte P, Marin B, Fontaine S, Boubaddi NE, Clement MP, Sautereau D, Loustaud-Ratti V, Gourcerol G, Monteil J. Peroral endoscopic pyloromyotomy is efficacious and safe for refractory gastroparesis: prospective trial with assessment of pyloric function. Endoscopy. 2019 Jan;51(1):40-49. doi: 10.1055/a-0628-6639. Epub 2018 Jun 12.
Results Reference
result
Learn more about this trial
Feasibility of Endoscopic Pylorotomy in the Treatment of Refractory Gastroparesis, Pilot Study.
We'll reach out to this number within 24 hrs